
COMPARATIVE GENOMIC HYBRIDIZATION STUDY OF INVASIVE TRANSITIONAL CELL CARCINOMAS OF THE URINARY BLADDER OF BULGARIAN PATIENTS Zaharieva B1, Damianov Ch2, Tabakov V2, Tzingilev B2, Nikolov I1, Georgiev Ch3, Toncheva D1 *Corresponding Author: Toncheva D.
Department of Medical Genetics,
Medical University Sofia,
2 Zdrave str,
1431 Sofia, Bulgaria
Tel/Fax: + 359 2 9520357
email: draga@spnet.net
page: 31
|
Abstract
Prognosis in bladder cancer is clearly worse if cancer cells reach the muscle bladder wall (stage pT2-4) compared to minimally invasion (stage pT1) where cancer cells do not go beyond lamina propria of the urinary bladder. Increased genomic instability is suspected to increase the malignant potential of cancer cells.
The aim of our study was to perform a comparative genomic hybridization for whole tumor genome scan of invasive transitional cell carcinomas of the urinary bladder of Bulgarian patients in order to compare the genomic instability of pT1 and pT2-4 invasive tumors as well as to look for specific chromosomal imbalances associated with muscle invasion.
Our results did not show significant differences in the total number of chromosomal aberrations between pT1 and pT2-4 (P=0.2030). This is consistent with models suggesting two different entities of bladder neoplasms, one (pTaG1/G2) being genetically stable with low risk of progression, and the other one (pTa G3, pT1-4) with a high degree of genetic instability and high risk of progression. Deletions were more frequent in pT2-4 almost reaching statistical significance ( mean 0.13 deletions per case in pT1 versus 1.4 in pT2-4; P=0.0610). Some of the genetic alterations were significantly linked to the tumor stage - gains at 5p, 17q and 20q (P=0.0198, P=0360 and P=0.0336 ).
In summary, our study demonstrated that not the total genome instability but specific chromosomal aberrations (5p+, 17q+ and 20q+) are associated with muscle invation of urinary bladder cancer.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|